Supplemental File “Text Summary”

There are 5 supplemental files with this submission and all are pdf. Each file contains a figure with a figure legend located beneath it. The first 3 visually describe methods used. The 4th and 5th display data that validate our experimental approach.
Supplemental Figure 1

Induction of Allergic Airway Disease

16 ug of HDM intratracheally every other day 7 times

Supplemental Figure 1. *Induction of Allergic Airway Disease by House Dust Mite Extract*
Supplemental Figure 2

Induction of Airway Disease by IL-13

2 or 3 ug of IL-13 intratracheally daily for 7 days

Supplemental Figure 2. Induction of Airway Disease by Exogenous IL-13
Supplemental Figure 3

Measurement of Cytokine Levels by In Vivo Cytokine Capture Assay (IVCCA)

16 ug of HDM intratracheally every other day 7 times

Doses of House Dust Mite Extract

Injection of blocking anti-cytokine biotinylated Abs
Bleed 24hrs later
Supplemental Figure 4. Cre-constructs do not alter AHR independently of IL-4Ra.
Wild type mice were bred to CC10-Cre+ SMP8-Cre+ IL-4Ra/- mice to produce mice that were IL-4Ra+/+ and carried one, two or neither Cre-constructs.
Cre-expression was driven by the CC10 or the SMP8 promotor but could not act upon the wild type allele.
These IL-4Ra+/+ mice were treated i.t. with saline or 3 µg of IL-13 (lot #2) daily for 7 days.
A, Invasive measurement of airway sensitivity to methacholine in all experimental groups.
B, Invasive measurement of AHR when IL-13-treated mice were pooled according to their CC10-Cre genotype.
C, Invasive measurement of AHR when IL-13-treated mice were pooled according to their SMP8-Cre genotype.
Groups treated with IL-13 did not statistically differentiate from one another.
Supplemental Figure 5. IL-13-treated CCSP-Cre+/- IL-4Rαflox/- mice have considerably decreased AHR and considerable, but incomplete, inhibition of GCM as compared to CCSP-Cre-/- IL-4Rαflox/- mice. IL-4Rαflox/- mice were treated i.t. with 2 µg of IL-13 daily for 7 days. A. Invasive measurement of AHR. B. Quantitation of GCM. C. Distribution of residual GCM in the IL-13-treated CCSP-Cre+/- mice. D. AHR when CCSP-Cre+ mice that had high residual GCM were excluded. A-C. Results represent 10, 21 and 8 mice for the groups: Cre- + IL-13, CCSP-Cre+/- + IL-13 and both genotypes + saline, respectively. D. The group CCSP-Cre+/- + IL-13 represents 11 mice. **, p < 0.01; ***, p < 0.001.